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Correlation of histology to rejection reversal: A Thymoglo- sary to distinguish between refractory rejection and
bulin Multicenter Trial report other causes of continued dysfunction such as the devel-
Background. Histology may provide a link between clinical opment of drug-induced nephrotoxicity. Previously,response to antirejection therapy and graft function. In a subset
most trials assessing the efficacy of rejection treatmentof centers, renal biopsy was a secondary end point for the
have used clinical parameters as primary end pointsThymoglobulin Multicenter Trial.
Methods. Thirty-eight patients had a protocol biopsy one to [4–6]. Recently, however, more objective criteria for
two weeks following the end of therapy. Inclusion and post- quantitation of allograft inflammation have been devel-
treatment biopsies were graded and scored according to Banff oped [7, 8]. The development of such a schema has stimu-criteria by a central pathologist who was blinded to the type
lated interest in the use of histological information de-and outcome of therapy and the timing of the biopsy.
rived from the protocol biopsies as end points in rejectionResults. The majority of patients (31 of 38) had moderate
rejection on their inclusion biopsy. An improvement of at least trial analysis. The advantage of histological end points
one Banff grade occurred in 58% of the patients. The treatment in rejection trials may provide an explanation for inade-
was clinically successful in 33 patients, but two thirds of the
quate therapeutic response, which may be crucial in in-patients (25 out of 38) demonstrated residual inflammation in
terpreting trial outcomes. Moreover, the histologicalthe graft. The degree of improvement of inflammation was
proportionate to rejection severity (P 5 0.006). Banff scoring schema provide a way to quantitate objectively the
indicated that residual inflammation was less in Thymoglo- changes in graft inflammation in response to therapy and
bulin-treated patients than in those receiving Atgam (P , 0.05) to compare quantitatively the histological improvement
and correlated with the incidence of recurrent rejection (P 5
under various antirejection protocols. Finally, graft his-0.015).
tology early after treatment may prove important in theConclusions. These data demonstrate a discrepancy be-
tween clinical and histological resolution of acute renal allo- correlation of the long-term graft survival, a crucial end
graft rejection. Residual infiltrates in the graft following rejec- point for therapeutic success of rejection therapy.
tion therapy are common and, despite clinical improvement, Limitations for the use of post-treatment protocolmay indicate an increased risk for recurrent rejection.
biopsies as an efficacy end point are related to the general
inexperience with postrejection graft changes. First, the
sequence and timing of the resolution of the cellular and
The success of antirejection therapy is assessed by
vascular changes of rejection are, at best, incompletely
clinical and biochemical parameters that measure im-
understood, and thus, the question of the best time point
provement in graft function, rather than by histological
to assess for complete histological reversal of rejection
evidence of resolution of graft inflammation [1–3]. Biop-
is still unanswered. Second, the existence of a tight corre-sies following rejection therapy have traditionally been
lation between clinical and histological resolution of re-diagnostic biopsies, indicated by inappropriate recovery
jection is still doubtful [9]. Third, the relevance of cellularof graft function. In this event, allograft biopsy is neces-
inflammation in stable renal allografts is undefined [10,
11]. In fact, the few studies on postrejection treatment
biopsies describe a discrepancy between graft histologyKey words: kidney transplant, biopsy, acute rejection, Banff histology,
Atgam, rejection therapy. and function (abstract; Chavers, Am Soc Transplant Phy-
sicians 12:261, 1993) [9]. Persistent graft inflammationReceived for publication December 22, 1997
despite clinical reversal of acute rejection occurred withand in revised form October 1, 1998
Accepted for publication January 11, 1999 an unexpected, relatively high frequency in these reports.
The increasing speculation linking “silent” graft cellular 1999 by the International Society of Nephrology
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infiltrates to chronic graft damage continues to stimulate these biopsies, but results of their review were included
interest in examining the completeness of the resolution as a secondary end point in the study analysis.
of histological graft inflammation in postrejection biop-
Biopsy materialsies and the possible relationship between post-treat-
ment histology and subsequent clinical outcome. Enrollment in the study and the analysis of entry strati-
We were interested in testing the validity of using fication were based on the histological diagnosis made
protocol postrejection biopsies as an end point of thera- at each center. At the end of the clinical trial, pretreat-
peutic response. A multicenter, double-blind, phase III ment and post-treatment biopsies from the participating
clinical trial was conducted to compare the efficacy of centers were sent for central blinded review. The results
Thymoglobulin to Atgam in the treatment of renal allo- of the central pathologist review were used in this report.
graft rejection [12]. The study design encouraged post- Centralized pathology was favored to minimize interob-
treatment protocol biopsies as a means to enhance the server error or bias in the interpretation of histological
assessment of rejection reversal by therapy. An analysis changes and thereby ensure more consistent grading and
of the postrejection biopsy findings, in correlation with scoring of the allograft histology. Each biopsy was as-
a therapeutic response and with the initial rejection pa- signed a study number that did not distinguish pretreat-
thology, is the subject of this report. ment from post-treatment biopsies. The central patholo-
gist review was not only blinded to the status of the
biopsy (that is, inclusion biopsy vs. post-treatment proto-METHODS
col biopsy), but also to the transplant center, patient,Study design
and therapeutic arm. A minimum of two hematoxylin
This study was designed as a part of the U.S. multicen- and eosin and period acid-Schiff stained slides were re-
ter phase III clinical trial comparison of the efficacy and viewed for each biopsy. Graft histology was recorded
safety of Thymoglobulin versus Atgam in the treatment according to strict Banff criteria, with four levels of rejec-
of acute renal allograft rejection. The randomized, pro- tion entered: borderline change, grade I, grade II (A or
spective, double-blinded trial was conducted at 25 U.S. B specified), and grade III. Biopsies were scored individ-
centers and included 163 patients randomized based on ually for the intensity of interstitial inflammation, glo-
the histological classification of acute rejection. The merulitis, tubulitis, and intimal arteritis. In addition, a
study protocol required an inclusion biopsy that was narrative description of the pathology was provided.
graded according to the Banff schema. Only patients After a blinded pathology review of the study biopsies,
with Banff grade II or III acute rejections were recruited
the biopsy codes were unmasked, and accordingly, pre-
into the study. Patients with Banff grade I rejections
treatment and post-treatment biopsies were grouped forwere included if they demonstrated steroid resistance.
data analysis. Histological improvement in the post-All biopsies had to be obtained within 24 hours prior
treatment protocol biopsies was defined a priori as anto the start of the antilymphocyte treatment. Standard
improvement of at least one grade in the Banff classifica-inclusion and exclusion criteria were used and have been
tion scale, from the rejection grade of the inclusionreported [12]. Patients received either Thymoglobulint
biopsy.(1.5 mg/kg/day), a rabbit immune globulin (SangStat
Forty-four paired pretreatment and post-treatment re-Medical Corporation, Menlo Park, CA, USA), or At-
nal allograft biopsies were initially identified. Six biopsygamt (15 mg/kg/day), a horse antilymphocyte globulin
pairs were excluded from this analysis for the following(Pharmacia & Upjohn, Kalamazoo, MI, USA), for 7 to
reasons: (a) the biopsy material available for review was14 days via a central line. The withdrawal of patients for
considered inadequate by Banff criteria (N 5 4); anda lack of efficacy was allowed in this double-blinded
(b) there were major, unreconciled discrepancies be-study if after five days of therapy clinical parameters
tween the local and central pathology diagnoses (N 5 2).indicated a lack of reversal or a biopsy confirmed worsen-
ing of rejection.
Statistical analysisThe primary end point of therapy success was a decline
Statistical analysis was performed using a microcom-in serum creatinine to or below the baseline creatinine
puter software program, JMPt Version 3.1.5 Softwareon two consecutive measurements taken at least two
for Statistical Visualization on the Applet Macintoshtdays apart. Several clinical secondary end points were
(SAS Institute Inc., Cary, NC, USA). One-way analysismeasured, including graft survival at day 30, serum creat-
of variance was used to determine the difference betweeninine response at day 30 (as a percentage of baseline),
groups as mean comparisons for quantitative data. Theand biopsy improvement at the end of therapy. Protocol
chi-square test was used to compare categorical data.biopsies were encouraged as part of the study design
Results were considered to be of statistical significanceand were specified to be obtained within one week of
the end of therapy. No clinical decisions were made on for P values of less than 0.05.
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Table 1. Demographic and patient characteristics of individuals vidual renal compartments revealed that interstitial, tu-
receiving post-treatment protocol biopsies after therapy with
bular, vascular, glomerular, and total sum scores wereeither Thymoglobulin or Atgam for acute rejection
not different in inclusion biopsies of patients randomized
Thymoglobulin Atgam to either treatment arm. However, differences were seenTotal patients, N 82 81
for interstitial, tubular, and total sum score in post-treat-
Posttreatment biopsy study patients, N 20 18
ment protocol biopsies, favoring patients receiving Thy-Race (Caucasian), N (%) 11 (53) 10 (58)
Gender (male), N (%) 14 (71) 13 (74) moglobulin treatment for rejection (Table 4). In addi-
Age, mean 6 sd 39617 43610 tion, in the subgroup of 38 patients receiving protocol
CAD/LRD/LURD % 65/29/6 68/21/11
biopsies, significantly more recurrent rejection occurredPRA%, mean 6 sd 8619 367
Days to rejection, median (range) 48 (5–1457) 36 (5–2057) in the Atgam group (47%) than in the Thymoglobulin
Donor age, years 34612 36617 group (12%, P 5 0.02). There was a trend for an in-
CMV positive, N (%) 13 (65) 9 (53)
creased incidence in graft loss in Atgam-treated patients
Abbreviations are: CAD, cadaver donor; LRD, living related donor; LURD, (21%) than in patients receiving Thymoglobulin (0%,living unrelated donor; PRA, panel of reactive antibodies; CMV, cytomegalo-
virus. P , NS).
To determine whether the length of therapy had an
effect on the histological improvement in rejection grade,
an analysis was performed to evaluate differences if anti-
RESULTS rejection therapy had been received for seven days or
One hundred and sixty-three patients were random- less or more than seven days. The creatinine response
ized to both treatment arms (Thymoglobulin, N 5 82; was not different: 74% of baseline serum creatinine level
Atgam, N 5 81). Of the patients randomized to Thymo- for seven days or less of therapy or 76% for more than
globulin, 10 had mild rejection (Banff grade I) with ste- seven days of therapy (P 5 0.84). Likewise, length of
roid resistance; 58 had moderate acute rejection (grade therapy was correlated to the Banff grade at the post-
II), and 14 had severe acute rejection (grade III). This treatment protocol biopsy, and no difference was found
was not different from the patients randomized to Atgam (P 5 0.70). If seven days or less of therapy were received,
(8, grade I; 59, grade II; 14, grade III). Rejection reversal 1 of 11 patients (9%) had borderline acute rejection on
was achieved more often in Thymoglobulin-treated pa- the post-treatment protocol biopsy. Two of 11 patients
tients (88%) compared with Atgam-treated patients (18%) had Banff grade I acute rejection. Four of 11
(76%, P 5 0.027). The full results of efficacy and safety patients (36%) had Banff grade II acute rejection. No
comparisons of these antilymphocytes have been pre- patients had Banff grade III, and 4 of 11 patients (36%)
viously reported [12]. had no rejection on the biopsy. Compared with those
receiving more than seven days of therapy, 5 of 27 pa-
Relationship of antilymphocyte treatment arm to tients (19%) had borderline acute rejection. Five of 27
postrejection protocol biopsies patients (19%) had Banff grade I acute rejection. Six of
Nine centers obtained 38 protocol post-treatment 27 patients (22%) had Banff grade II acute rejection.
biopsies as specified by the study design. The demo- Two of 27 patients (7%) had Banff grade III, and 9 of
graphics of the patients having the biopsy are displayed 27 patients (33%) had no rejection on the post-treatment
in Table 1 and were not different from the demographics protocol biopsy.
of the overall study participants. As with the total study
Clinicopathological correlates to histologicalpopulation, the majority of patients undergoing protocol
improvement in post-treatment protocol biopsiesbiopsies had moderate rejection on their inclusion biopsy
(31 of 38) with few patients with grade I (N 5 2) or grade A secondary analysis was conducted in an attempt
III (N 5 5) acute rejection. Histological improvement of to understand the clinicopathological correlates to the
at least one Banff grade, as defined in the study protocol, histological improvement in acute rejection changes re-
was seen with equal frequency in patients receiving ei- gardless of treatment type. All 38 patients having a post-
ther antilymphocyte treatment (Table 2). The treatment treatment protocol biopsy were grouped according to
was clinically successful in 94% of patients receiving whether their post-treatment protocol biopsy indicated
Thymoglobulin and in 79% of patients receiving Atgam, an improvement by at least one Banff grade from the
but only 35 and 33% of the respective biopsies demon- inclusion biopsy. An improvement in the Banff grade
strated total resolution of the rejection on the repeat was inversely proportional to the severity of rejection
biopsy. The grade of the residual histological changes on the inclusion biopsies (P , 0.006; Table 5). This
by treatment group is shown in Table 3. There was a inverse relationship between initial severity and subse-
trend toward milder residual histological changes in the quent improvement was also apparent for individual his-
post-treatment protocol biopsies of patients receiving tological compartment scores, interstitial (P , 0.008),
tubular (P , 0.055), and vascular (P , 0.093; Fig. 1).Thymoglobulin. Scoring of histological changes in indi-
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Table 2. Improvement in Banff grade after treatment with either Thymoglobulin or Atgam for acute rejection
Thymoglobulin Atgam
Inclusion biopsy
rejection severity Improveda Not improved Improveda Not improved
Grade I, N (%) 1 (100%) 0 0 1 (100%)
Grade II, N (%) 10 (59%) 7 (41%) 8 (58%) 6 (42%)
Grade III, N (%) 2 (199%) 0 1 (34%) 2 (66%)
Total 13 (65%) 7 (35%) 9 (50%) 9 (50%)
P 5 NS.
a Defined by study protocol as one Banff grade level improvement on post-treatment protocol biopsy from the inclusion biopsy
Table 4. Histologic renal compartment scores in inclusion biopsiesTable 3. Banff grade of residual inflammation after therapy with
either Thymoglobulin or Atgam for acute rejection and post-treatment protocol biopsies of patients receiving either
Thymoglobulin or Atgam for acute rejection
Banff Grade Thymoglobulin (%) Agram (%)
Post-treatment protocol
Borderline 4 (23) 1 (6) Inclusion biopsy biopsy
Grade I 5 (24) 2 (11)
Grade II 4 (18) 7 (39) Thymoglobulin Atgam Thymoglobulin Atgam
Grade III 0 2 (11)a
Interstitial 2.260.2 2.2 60.2 0.860.2 1.5 60.2aNo rejection 7 (35) 6 (33)
Tubular 2.160.2 2.2 60.2 0.960.2 1.5 60.2bClinical successb 19 (94) 14 (79)
Vascular 0.760.3 0.9 60.2 0.360.2 0.5 60.2
a P 5 0.14, chi-square Glomerular 0 0.160.0 0 0
b Defined as a decline in serum creatinine to or below serum creatinine on Sum score 5.0 60.5 5.3 60.5 2.060.5 3.560.5c
two successive measurements obtained at least two days apart
a P 5 0.025, b P 5 0.096, c P 5 0.044, one-way analysis of variance, difference
between Thymoglobulin and Atgam on post-treatment protocol biopsy
Interestingly, none of the clinical parameters monitored
as part of the study protocol (neither primary end point, groups, and four were from the Atgam group. An analy-
secondary end points, days to protocol biopsy, nor creati- sis of biopsy improvement between study groups, when
nine level at the time of protocol biopsy) correlated with the second reading was considered, continued to indicate
histological improvement in rejection grade (Table 6). no difference between the two therapies (Thymoglo-
Additionally, after the central pathologist was un- bulin, Banff grade improvement, 80%; Atgam, Banff
blinded as to the timing of the biopsy (that is, inclusion grade improvement, 72%).
vs. post-treatment biopsy), a second review of the post-
treatment biopsy was performed. When numerical scores Relationship between recurrent rejection and
histological changes on post-treatmentand intensity of histological lesions were compared be-
tween the inclusion and post-treatment protocol biop- protocol biopsies
sies, seven post-treatment protocol biopsy cases showed In the 38 patients receiving a post-treatment protocol
a discrepancy from the blinded reading. In five cases, biopsy, 11 developed recurrent rejection (31%), of which
the intensity of the inflammation and the scoring for 4 had experienced a successful response to the initial
interstitial inflammation was reduced from scores of 2 therapy. Demographic and clinical criteria did not differ-
or 3 to scores of 0, 1, or 2. Also, tubulitis in these cases entiate patients with recurrent rejection (Table 7). Histo-
was reduced by the number of tubules with inflammation. logical grading indicated equivalent sum scores from the
However, according to the strict definition of the Banff inclusion biopsy for patients with and without recurrent
criteria, if any tubule has a high score, the Banff grade rejection. Importantly, the only parameter associated
is higher, thus resulting in a perceived lack of improve- with the occurrence of recurrent rejection was the histo-
ment by Banff grade. In two post-treatment protocol logical grading of the post-treatment protocol biopsy as
biopsy specimens, the vascular lesions were present in expressed by the Banff sum score. The sum score on the
the form of fibrinoid changes, which resulted in an assess- post-treatment protocol biopsy in patients who subse-
ment of no improvement from the inclusion biopsy. quently developed recurrent rejection was 4.2 6 0.6,
However, the vessel wall and the parenchyma exhibited which was significantly higher than those without recur-
less inflammation when the numerical scores were re- rent rejection (2.2 6 0.4, P 5 0.015).
viewed. In both of these situations, the blinded post-
treatment protocol biopsy reading was assessed as no
DISCUSSIONimprovement in Banff grade over the inclusion biopsy
reading when inflammation was actually improved. Of Renal allograft half-life is dependent on a multitude
of immunological and nonimmunological factors that in-these seven cases, three were from the Thymoglobulin
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Table 5. Relationship between the observed improvement in post-
treatment protocol biopsies and Banff grade of inclusion biopsy
Post-treatment protocol biopsy
Inclusion biopsya
rejection grade Improvedb Not improved
Grade I, N (%) 3 (30) 7 (70)
Grade II, N (%) 15 (63) 9 (37)
Grade III, N (%) 4 (100) 0c
a Biopsy taken at the time of rejection, prior to antirejection therapy
b Defined by study protocol as a one Banff grade level improvement on post-
treatment protocol biopsy from the inclusion biopsy
c P 5 0.006, chi-square
Fig. 1. Histological renal compartment score improvement (defined as
one Banff grade level of improvement) from inclusion biopsy to post-
treatment protocol biopsy following antilymphocyte antibody therapy
for acute rejection. Symbols are ( ) Banff score 1; ( ) Banff score 2;
(j) Banff score 3; *P , 0.008; **P , 0.055; #P , 0.093.fluence the progression to chronic rejection. Of these
factors, acute rejection has been strongly linked to the
development of chronic rejection, particularly acute re-
jection associated with recurrent rejection, acute rejec- subsets seen during treatment (abstract; Woodle, Am
tions of late onset, and severe acute rejection [13–18]. Soc Transplant Physicians 16:260, 1997) [12]. The in-
Although the exact mechanism by which acute rejection creased efficacy of Thymoglobulin was also demon-
influences the long-term graft survival is speculative, it strated in this subset of patients by the trend toward a
is presumed that persistent, subclinical rejection could higher rate of histological improvement of one or more
progress to clinically apparent chronic injury. Defining Banff grade levels in the post-treatment protocol biop-
whether persistence of graft infiltrates following rejec- sy; 65% of Thymoglobulin-treated patients improved,
tion treatment could be correlated to any clinical par- whereas only 50% of patients receiving Atgam im-
ameters could help in identifying patients at a risk for proved. However, only one third of the patients demon-
long-term allograft dysfunction. Thus, the link between strated complete resolution of rejection histology in both
complete histological resolution of acute rejection and treatment arms.
clinical parameters of rejection reversal was the purpose Residual rejection histology as measured by Banff
of this analysis. Our data demonstrate that within the scoring of various renal compartments was worse in At-
time frame chosen for the post-treatment protocol gam-treated patients, whereas Thymoglobulin-treated
biopsy, there was a lack of correlation between clinical patients had significantly lower interstitial, tubular, and
rejection reversal and histological resolution of rejection. total sum scores. The lack of difference in vascular and
Our most common finding was a persistence of some glomerular scores was likely due to the fact that mean
histological inflammation despite functional improve- vascular and glomerular scores on inclusion biopsy were
ment. These histological changes carried a prognostic less than one in both treatment arms. The ability to
significance in a subset of cases in which the inflammation demonstrate significant differences in residual rejection
severity had a Banff sum score of 4.0 or more. In those histology between treatment arms may indicate that
cases, inflammation was associated with recurrent rejec- compartment and total sum scoring is a more sensitive
tion, indicating that relying solely on renal function im- measure than the parameter chosen prospectively in the
provement may lead to inadequate treatment of rejection study protocol (that is, improvement by one Banff grade
episodes. Whether this discrepancy in functional im- level), which did not demonstrate a difference between
provement and histological outcomes can explain the treatment arms. Thus, compartment scoring by Banff
correlation between acute rejection episodes and chronic schema may be more relevant for future immunosup-
allograft deterioration is unknown. pressive trials than grading of rejection. In addition,
The results of the randomized study demonstrated when using the Banff schema in protocols with post-
significant differences in the rate of rejection reversal in treatment protocol biopsies, the pathologist should not
patients treated with Thymoglobulin versus Atgam [12]. be blinded as to whether the biopsy was taken as an
A similar trend was observed in the subset of patients inclusion biopsy or following therapy. Because the nu-
included in this report who received a post-treatment merical scores may be more sensitive for indicating im-
protocol biopsy (94% for Thymoglobulin vs. 79% for provement, blinding to only the study therapy arm would
Atgam, P 5 0.17), although significance was not achieved be more appropriate for the pathology reading. Possibly
in the small number of patients. The increased potency two layers of reading should occur: first, a reading in
of Thymoglobulin as a rejection reversal agent can be which the timing of the biopsy is known, and second, a
explained by the multiplicity of its target epitopes and reading in which the inclusion biopsy is compared di-
rectly with the post-treatment protocol biopsy.the more complete and sustained depletion of T-cell
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Table 6. Comparison of clinical parameters and observed histologic improvement on post-treatment protocol biopsy specimens
after therapy for acute rejection
Biopsy Biopsy
Parameter improveda not improved P value
Clinical rejection reversal,b N (%) 17 (81) 14 (93)
Days to post-treatment biopsy, mean 6 sd 1566 14 68
Serum creatinine parameters, mean 6 sd
At rejection, mg/dl 4.962.7 4.3 63.3
At post-treatment biopsy, % of rejection creatinine 82639 85 638
At post-treatment biopsy, mg/dl 3.662.3 2.7 61.7 0.23
At 30 days, % of rejection creatinine 76639 82 648
At 30 days, mg/dl 4.263.4 2.2 60.6 0.05
a Defined as a one Banff grade level improvement on post-treatment protocol biopsy from the inclusion (baseline, rejection) biopsy
b Defined as a decline in serum creatinine to or below baseline serum creatinine on two successive measurements obtained at least two days apart
Table 7. Correlation of Banff sum score and clinical parameters of rejection to occurrence of recurrent rejection
Parametera Recurrent rejection No recurrent rejection
Rejection creatinine, mg/dl 3.961.7 5.0 63.3
Creatinine response, % of baseline creatinine 69622 77 635
Primary success, N (%) 13 (55) 25 (65)
Post-treatment protocol biopsy creatinine, mg/dl 2.561.3 3.6 62.4
Serum Creatinine at 30 days, mg/dl 4.264.1 3.0 61.9
Inclusion biopsy sum score 4.8 62.0 5.2 62.0
Post-treatment protocol biopsy sum score 4.2 62.1 2.262.1b
a All values are mean 6 sd
b P 5 0.015, one-way analysis of variance, difference between recurrent rejection and no recurrent rejection
The lack of correlation between clinical measures of ment. They did demonstrate, however, that improve-
ment in serum creatinine was not associated withrenal function and histology was suggested by Kerr and
Atkins, who demonstrated a lack of correlation between histological resolution in one third of their patients, indi-
cating a lack of correlation between clinical improvementthe clinical outcome and histology in OKT3-treated pa-
tients. In their patients, some improvement in post-treat- and histological resolution. Additional support of this
observation has been described recently in patients re-ment biopsies at day 5 was noted in all patients, despite
the fact that three grafts were lost to irreversible rejection ceiving steroid treatment for rejection (abstract; Maz-
zuchi, Am Soc Transplant Physicians 16:135, 1997). It is[19]. Similarly, Chavers et al demonstrated in a pilot
study that 8 of 13 patients treated successfully for acute recognized that some of this residual rejection histology
could be explained by a lack of homogeneity of infiltratesrejection had histological features consistent with acute
rejection on biopsies obtained six weeks following treat- and the potential variability of needle biopsies. However,
based on the results of this study and the available litera-ment (abstract; Chavers et al, Am Soc Transplant Physi-
cians 12:261, 1993). They postulated that the histological ture, it seems to follow patients longitudinally after anti-
rejection treatment to determine the fate and progres-evidence of acute rejection may persist in some patients
and that this smoldering subclinical acute rejection may sion of these residual histological changes.
As part of the design of this prospective randomizedbe a factor in the development of chronic rejection, de-
spite seemingly successful response to therapy. Recently, study, histological criteria were used for the first time
for stratification of patients into treatment arms. In anWoodle et al reported a series of post-treatment protocol
biopsies obtained during Tacrolimus therapy for refrac- attempt to include objective histological criteria as end
points for treatment success, an improvement in onetory renal rejection [9]. Biopsies were obtained at time
of inclusion in the Tacrolimus treatment protocol, one Banff grade level was chosen as an end point. In addition,
we collected data using Banff criteria for scoring theweek after initiation of therapy and weekly thereafter
if there was a lack of clinical response. Their results changes in renal compartments (interstitial, glomerular,
tubular, and vascular) of both the inclusion biopsy anddemonstrated that 40% had persistence of the rejection
histology on the post-treatment protocol biopsy. The the post-treatment protocol biopsy. Improvement in
Banff grading and in interstitial, tubular, and vasculardata from Woodle’s report were somewhat different
from our findings in that histological resolution of rejec- scoring was inversely related to the severity of rejection
scores. Severe rejection, particularly that with vasculartion more commonly preceded biochemical improve-
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changes, has been demonstrated in other studies to have portional to the severity of the initial histological scoring.
The scoring of infiltrates using Banff classification dida poor outcome (40% were classified as irreversible)
and to be responsive to treatment with antilymphocyte not correlate with clinical parameters of rejection rever-
sal, but had prognostic significance in patients for whomagents [20]. Clinical response to antirejection therapy
was not associated, however, with the selected histologi- the residual infiltrate score was greater than 4.0. The
long-term significance of the persistent infiltrates is un-cal outcome, that is, an improvement of one Banff grade
level. In the cases in which clinical rejection reversal clear at this time. More prospective studies should proba-
bly include longitudinal protocol biopsy surveillance tooccurred, there were an equal number of post-treatment
protocol biopsies with or without improvement over the determine the histological and functional outcomes of
patients with residual rejection histology following suc-inclusion biopsy, with two thirds of the biopsies demon-
strating various degrees of residual rejection. In addition, cessful therapy for acute rejection.
none of the routine clinical parameters used to judge
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